These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 26848109)

  • 1. The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins.
    Santos JA; Kondo MY; Freitas RF; dos Santos MH; Ramalho TC; Assis DM; Juliano L; Juliano MA; Puzer L
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1485-9. PubMed ID: 26848109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cysteine proteases by a natural biflavone: behavioral evaluation of fukugetin as papain and cruzain inhibitor.
    Assis DM; Gontijo VS; de Oliveira Pereira I; Santos JA; Camps I; Nagem TJ; Ellena J; Izidoro MA; dos Santos Tersariol IL; de Barros NM; Doriguetto AC; dos Santos MH; Juliano MA
    J Enzyme Inhib Med Chem; 2013 Aug; 28(4):661-70. PubMed ID: 22468751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition profiles of human tissue kallikreins by serine protease inhibitors.
    Luo LY; Jiang W
    Biol Chem; 2006 Jun; 387(6):813-6. PubMed ID: 16800745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unleashing the therapeutic potential of human kallikrein-related serine proteases.
    Prassas I; Eissa A; Poda G; Diamandis EP
    Nat Rev Drug Discov; 2015 Mar; 14(3):183-202. PubMed ID: 25698643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrido-imidazodiazepinones as a new class of reversible inhibitors of human kallikrein 7.
    Arama DP; Soualmia F; Lisowski V; Longevial JF; Bosc E; Maillard LT; Martinez J; Masurier N; El Amri C
    Eur J Med Chem; 2015 Mar; 93():202-13. PubMed ID: 25682203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel inhibitory activity for serine protease inhibitor Kazal type-3 (Spink3) on human recombinant kallikreins.
    Assis DM; Zalazar L; Juliano MA; De Castro R; Cesari A
    Protein Pept Lett; 2013 Oct; 20(10):1098-107. PubMed ID: 23590280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors.
    Pakkala M; Hekim C; Soininen P; Leinonen J; Koistinen H; Weisell J; Stenman UH; Vepsäläinen J; Närvänen A
    J Pept Sci; 2007 May; 13(5):348-53. PubMed ID: 17436344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins.
    Tan X; Bertonati C; Qin L; Furio L; El Amri C; Hovnanian A; Reboud-Ravaux M; Villoutreix BO
    Eur J Med Chem; 2013; 70():661-8. PubMed ID: 24211642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody reveals a potential role in airway diseases.
    Sexton DJ; Chen T; Martik D; Kuzmic P; Kuang G; Chen J; Nixon AE; Zuraw BL; Forteza RM; Abraham WM; Wood CR
    Biochem J; 2009 Aug; 422(2):383-92. PubMed ID: 19527222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of IGFBP-3 fragments generated by KLK2 and prevention of fragmentation by KLK2-inhibiting peptides.
    Hekim C; Riipi T; Weisell J; Närvänen A; Koistinen R; Stenman UH; Koistinen H
    Biol Chem; 2010 Apr; 391(4):475-9. PubMed ID: 20180640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biflavonoids inhibited phosphatase of regenerating liver-3 (PRL-3).
    Choi SK; Oh HM; Lee SK; Jeong DG; Ryu SE; Son KH; Han DC; Sung ND; Baek NI; Kwon BM
    Nat Prod Res; 2006 Apr; 20(4):341-6. PubMed ID: 16644528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4.
    Swedberg JE; Nigon LV; Reid JC; de Veer SJ; Walpole CM; Stephens CR; Walsh TP; Takayama TK; Hooper JD; Clements JA; Buckle AM; Harris JM
    Chem Biol; 2009 Jun; 16(6):633-43. PubMed ID: 19549601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin Blocks the Inhibition of Tissue Kallikrein 1 by Kallistatin through Electrostatic Repulsion.
    Ma L; Wu J; Zheng Y; Shu Z; Wei Z; Sun Y; Carrell RW; Zhou A
    Biomolecules; 2020 May; 10(6):. PubMed ID: 32481593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2.
    Mize GJ; Wang W; Takayama TK
    Mol Cancer Res; 2008 Jun; 6(6):1043-51. PubMed ID: 18567807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leishmanicidal, antiproteolytic and antioxidant evaluation of natural biflavonoids isolated from Garcinia brasiliensis and their semisynthetic derivatives.
    Gontijo VS; Judice WA; Codonho B; Pereira IO; Assis DM; Januário JP; Caroselli EE; Juliano MA; de Carvalho Dosatti A; Marques MJ; Viegas Junior C; Henrique dos Santos M
    Eur J Med Chem; 2012 Dec; 58():613-23. PubMed ID: 23178961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule inhibitors of plasma kallikrein.
    Young WB; Rai R; Shrader WD; Burgess-Henry J; Hu H; Elrod KC; Sprengeler PA; Katz BA; Sukbuntherng J; Mordenti J
    Bioorg Med Chem Lett; 2006 Apr; 16(7):2034-6. PubMed ID: 16413183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution.
    Katz BA; Liu B; Barnes M; Springman EB
    Protein Sci; 1998 Apr; 7(4):875-85. PubMed ID: 9568894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.
    Walker AL; Denis A; Bingham RP; Bouillot A; Edgar EV; Ferrie A; Holmes DS; Laroze A; Liddle J; Fouchet MH; Moquette A; Nassau P; Pearce AC; Polyakova O; Smith KJ; Thomas P; Thorpe JH; Trottet L; Wang Y; Hovnanian A
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126675. PubMed ID: 31521475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A natural product biflavonoid scaffold with anti-tryptase activity.
    Fazio NF; Russell MH; Flinders SM; Gardner CJ; Webster JB; Hansen MDH
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Jan; 394(1):107-115. PubMed ID: 32840651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward the first class of suicide inhibitors of kallikreins involved in skin diseases.
    Tan X; Soualmia F; Furio L; Renard JF; Kempen I; Qin L; Pagano M; Pirotte B; El Amri C; Hovnanian A; Reboud-Ravaux M
    J Med Chem; 2015 Jan; 58(2):598-612. PubMed ID: 25489658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.